New Oral Medication Approved by FDA for Symptomatic Dermographism

The FDA has approved Novartis's oral medication, remibrutinib, as the first treatment for adults with symptomatic dermographism not adequately controlled by H1 antihistamines. This approval, based on Phase III trial data, offers a new therapeutic option for patients with this skin condition, expanding the drug's use beyond chronic spontaneous urticaria.